Gilead Sciences, Inc.
Gilead Sciences, Inc. (United States) holds 3 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 2 active ingredients and is linked to 2 FDA-registered manufacturing sites. 40 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Gilead Sciences, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/gilead-sciences-inc
Overview
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. With a portfolio of drugs in various stages of development, the company is known for its work in the fields of HIV, liver diseases, and cancer.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Gilead Sciences, Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Gilead Sciences, Inc. holds 3 active (7 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- COBICISTAT ON SILICON DIOXIDEActive2011-10-24
- ELVITEGRAVIRActive2011-10-21
- AMBISOME, LIPOSOMAL AMPHOTERICIN BActive1992-03-06
- LIPOSOMAL LURTOTECAN FOR INJECTION (OSI-211)Inactive2002-11-06
- LIPOSOMAL OSI-7904 FOR INJECTION (OSI-7904L)Inactive2002-06-28
- FK506LC AND PLACEBOInactive2001-10-12
- PMPA GELInactive1997-10-07
Registered manufacturing sites (2)
Physical sites registered with the US FDA and resolved to Gilead Sciences, Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
40 FDA enforcement records linked to this company.
- 4832026-02-18
Procedures not in writing, fully followed
- 4832026-02-18
Reserve samples identified, representative, stored
- 4832026-02-18
Annual visual exams of drug products
- 4832026-02-18
Procedures for sterile drug products
- 4832026-02-18
Scientifically sound laboratory controls
- 4832026-02-18
Following/documenting laboratory controls
- 4832026-02-18
Sterility/pyrogens - test methods written, followed
- recall — Class I2024-10-09
Presence of Particulate Matter: Presence of glass particle.
- 4832024-01-22
Late submission of 15-day report
- recall — Class I2022-01-05
Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
- 4832021-12-17
Validation lacking for sterile drug products
- 4832021-12-17
Training , Education , Experience overall
- 4832021-12-17
Procedures not in writing, fully followed
- 4832021-12-17
Buildings not maintained in good state of repair
- 4832018-07-17
Late submission of 15-day report
- recall — Class II2014-11-05
Defective Container; leaking around the cap
- recall — Class III2014-10-15
Presence of Foreign Substance: Truvada was found to contain small red silicone rubber particulates.
- 4832014-05-16
Theoretical yield statement including percentages
- 4832014-05-16
Investigations of discrepancies, failures
- 4832014-05-16
Procedures not in writing, fully followed
- 4832014-05-16
Air Supply
- 4832014-05-16
Complete instructions, procedures, specifications et. al.
- 4832014-05-16
Deviations from laboratory control requirements
- 4832014-05-16
Unlabeled filled containers controls
- 4832014-05-16
Reprocessing procedures lack steps to be taken
- recall — Class III2014-03-05
Presence of Foreign Substance: Red Silicone Rubber Particulates are Present in Drug.
- 4832014-01-15
Late submission of 15-day report
- recall — Class II2013-07-31
Lack of Sterility Assurance; During a routine simulation of the manufacturing of AmBisome, a bacterial contamination was detected in some media fill units. No contaminated batches have actually been identified in the finished product, but there is a possibility of contamination.
- recall — Class I2013-05-22
Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).
- warning_letter2010-09-21
FDA Warning Letter (drug product)
- 4832010-02-12
Review of representative number of batches
- 4832010-02-12
Cleaning / Sanitizing / Maintenance
- 4832010-02-12
Scientifically sound laboratory controls
- 4832010-02-12
Procedures for sterile drug products
- 4832010-02-12
Acceptance criteria for sampling & testing
- 4832010-02-12
Validation lacking for sterile drug products
- 4832010-02-12
Equipment to control conditions
- 4832010-02-12
Buildings not maintained in good state of repair
- 4832010-02-12
Aseptic Processing Area
- 4832010-02-12
Environmental Monitoring System
Is this Gilead Sciences, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.